Lexeo Expands Friedreich's Ataxia Pipeline With Mantle Buyout
- Lexeo Therapeutics agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four frataxin-targeting Friedreich ataxia programs to its AAV gene therapy pipeline.
- Early data on the lead acquired asset in a small patient cohort showed a meaningful improvement on a standard ataxia rating scale.
- Lexeo also struck new research collaborations with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy to pursue CNS-penetrant treatment approaches.
💡 Points
At $21.3M this is pocket change next to Telix-ITM, but strategically it's the smarter bolt-on: Lexeo already runs an AAV cardiac program in Friedreich's ataxia, so four more frataxin-targeting assets plus fresh CNS-penetrant collaborations with Weill Cornell, Vivet, and Apertura consolidate it as the depth player in a disease few large-caps are chasing.
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets ↗